SynthesisTransboundary and emerging diseases2026
Bovine Leukemia Virus: Global Prevalence and Localized Resurgence in China Revealed by an Integrated Meta-Analysis and Case Series.
Synthesis in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Bovine Leukemia Virus: Global Prevalence and Localized Resurgence in China Revealed by an Integrated Meta-Analysis and Case Series.Transboundary and emerging diseases · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bovine leukemia virus (BLV), the causative agent of enzootic bovine leukosis (EBL), causes substantial economic losses in the global cattle industry. While some regions have made progress in terms of control, the global epidemiological landscape and situation in China have not been fully elucidated. This study aimed to clarify the current global prevalence of BLV based on existing reported studies and investigate its alarming resurgence in China. Methods: We conducted an integrated study comprising a systematic review and meta-analysis of the global literature from 2010 to 2025 and a detailed case series investigation from Hubei Province, China. The meta-analysis followed PRISMA guidelines to calculate the pooled prevalence and identify risk factors. The case series included pathological examination, histopathology, and molecular detection (real-time PCR and nested PCR) to confirm BLV infection and genotype in clinical cases. Results: The meta-analysis, which included 44 studies, revealed a global pooled BLV prevalence of 23.24%, with a significant decline observed in studies published after 2018 (4.35%) compared with those published before 2018 (20.31%). Subgroup analyses indicated marked differences in detection rates across sample types and detection methods. Besides, significantly greater prevalence was also observed in cattle more than 12 months. In stark contrast to this global trend, the pooled prevalence in China was 16.80%, which masked a severe high-burden endemicity in Hubei Province, where a 49.41% positivity rate (126/255) was detected across three farms. Pathological and molecular analyses of four clinical cases from these farms confirmed BLV-induced lymphosarcoma and identified the circulating virus as genotype G6. Conclusion: This study delineates an apparent decline in reported BLV prevalence globally, contrasted with a severe localized resurgence in Hubei Province, China: an apparent decline in reported prevalence based on the available data in BLV prevalence, alongside a severe and ongoing resurgence in a major Chinese cattle-farming region. These findings underscore that national and global averages can obscure dangerous local epidemics. The situation in Hubei serves as a crucial warning, demanding immediate, targeted interventions, including enhanced surveillance, stringent biosecurity, and farmer education, to curb the spread of BLV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.